Dyadic International and BRIG BIO Sign Agreement to Develop Animal-Free Bovine Alpha-Lactalbumin
Dyadic International Inc. and BRIG BIO have signed an agreement to develop and commercialize animal-free bovine alpha-lactalbumin. BRIG BIO will fund the development and receive a global license to Dyadic's production strains. Dyadic will receive milestone payments, shared revenue, and co-marketing rights. The partnership aims to enhance the production and availability of alpha-lactalbumin for nutrition markets.
Dyadic International Inc. and BRIG BIO have announced the signing of a Development and Commercialization Agreement to jointly develop and commercialize recombinant bovine alpha-lactalbumin. Under the agreement, BRIG BIO will fully fund the development program and receive a global commercial license to Dyadic’s production strains developed in the Dapibus™ fungal expression system. Dyadic will receive access and milestone payments, long-term shared revenue participation tied to commercial sales, and co-marketing and sales rights. The partnership aims to advance the production and global availability of animal-free alpha-lactalbumin for use in nutrition markets. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyadic International Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9594173-en) on December 01, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
